1228014-09-2Relevant academic research and scientific papers
Discovery of Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor CC-223
Mortensen, Deborah S.,Perrin-Ninkovic, Sophie M.,Shevlin, Graziella,Zhao, Jingjing,Packard, Garrick,Bahmanyar, Sogole,Correa, Matthew,Elsner, Jan,Harris, Roy,Lee, Branden G. S.,Papa, Patrick,Parnes, Jason S.,Riggs, Jennifer R.,Sapienza, John,Tehrani, Lida,Whitefield, Brandon,Apuy, Julius,Bisonette, René R.,Gamez, James C.,Hickman, Matt,Khambatta, Godrej,Leisten, Jim,Peng, Sophie X.,Richardson, Samantha J.,Cathers, Brian E.,Canan, Stacie S.,Moghaddam, Mehran F.,Raymon, Heather K.,Worland, Peter,Narla, Rama Krishna,Fultz, Kimberly E.,Sankar, Sabita
, p. 5323 - 5333 (2015)
We report here the synthesis and structure-activity relationship (SAR) of a novel series of mammalian target of rapamycin (mTOR) kinase inhibitors. A series of 4,6- or 1,7-disubstituted-3,4-dihydropyrazino[2,3-b]pyrazine-2(1H)-ones were optimized for in v
PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO [2,3-B]PYRAZIN-2(1H)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE
-
Paragraph 0596, (2013/06/26)
Provided herein are compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, solid forms, isotopologues and metabolites thereof, and methods of their use for the treatment of a disease, disorder, or condition.
